Effectiveness and safety of switching to biosimilar infliximab and etanercept in patients with psoriasis

Abstract

Real‐life data on the effectiveness and safety of biosimilar and biologic drugs licensed for treatment of psoriasis is lacking. We retrospectively analysed patient records from 69 patients with moderate to severe psoriasis treated at the department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark in the period March 1st 2015 to October 1st 2017 who were administratively switched from the anti‐TNF biologics infliximab (Remicade) and etanercept (Enbrel) to the biosimilars Remsima and Benepali, respectively.

Approximately 25% of patients treated with infliximab and approximately 40% of patients treated with etanercept reported a worse effect after being switched from the original drug to its biosimilar. Quality of life was worse in approximately 30% after switching in both patient groups, respectively. The number of patients reporting adverse events increased in both groups.

This article is protected by copyright. All rights reserved.

http://bit.ly/2MDCrLe